Container and method for cell transduction
The use of fluoropolymer containers with aptamer sequences for viral vector binding improves transduction efficiency and simplifies the process, addressing inefficiencies in existing methods by promoting viral vector and target cell co-localization without manual coating.
Patent Information
- Application Number
- JP2024122524
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-12-30
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing transduction methods for introducing foreign DNA into target cells, such as hematopoietic cells and suspension cells, are inefficient and often require costly and time-consuming manual coating processes with enhancers like polybrene and retronectin, which can negatively impact cell viability.
A container with a fluoropolymer surface featuring functional groups and aptamer sequences that bind to viral vectors and cell receptors, facilitating efficient transduction without manual coating, using containers like bags, flasks, or tubes with integrated ports for media exchange.
Enhances transduction efficiency by promoting viral vector and target cell co-localization, simplifying the process and reducing the need for manual coating, while maintaining cell viability.
Smart Images

Figure 2024164028000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 954,735, filed December 30, 2019, which is incorporated by reference in its entirety.
[0002] Field of Disclosure The present disclosure generally relates to containers (such as bags) having a surface that includes one or more aptamer sequences. More specifically, the present disclosure relates to containers, such as bags, that include a fluoropolymer bound to an aptamer sequence that has binding affinity for one or more biological agents, and transduction methods using such containers. [Background technology]
[0003] Transduction, a method for introducing foreign DNA into target cells, for example by viral vectors, is important in several applications. For example, CAR T cell therapy is a cancer treatment in which T cells taken from a patient are transduced with a gene encoding a chimeric antigen receptor (CAR). The modified cells are able to bind to and kill cancer cells after expansion and reintroduction into the patient. Furthermore, viral transduction is routinely used in basic genetic research.
[0004] However, gene transfer from viral vectors can be inefficient for certain cell types, such as hematopoietic cells and other floating cells. Traditionally, transduction efficiency for such systems can be improved by the use of enhancers such as polybrene, protamine sulfate, or retronectin. Polybrene and protamine sulfate improve transduction efficiency by modifying the surface properties of target cells. However, these types of enhancers can have a negative effect on cell viability. Alternatively, retronectin (a polypeptide that contains a heparin-binding domain with binding affinity for viral particles and two cell-binding domains with binding affinity for VLA-4 and VLA-5 surface receptors) can improve transduction efficiency by promoting co-localization of viral vectors with target cells.
[0005] Conventionally, transduction enhancers such as RetroNectin must be manually coated onto containers prior to the transduction process. Because coated containers require special refrigeration and have a short shelf life, the relatively expensive and time-consuming coating process must usually be performed by the user performing the transduction process immediately prior to the process.
[0006] Thus, there remains a need for a simple, cost-effective, and / or time-effective system for cell transduction. Summary of the Invention
[0007] In one aspect, the present disclosure provides a container (e.g., in the form of a bag) having an outer surface and an inner surface, the inner surface comprising: Fluoropolymers; A plurality of functional groups attached to the fluoropolymer; and a first aptamer sequence bound to each of at least a portion of the functional groups and having binding affinity for the viral vector; Includes.
[0008] In another aspect, the disclosure provides a method of transduction comprising containing a viral vector and a target cell in a container as described herein.
[0009] Other aspects of the present disclosure will be apparent to those of skill in the art in view of the disclosure herein. [Brief description of the drawings]
[0010] [Figure 1] 1A-1D are schematic top view (top) and cross-sectional view (bottom) of a bag according to one embodiment of the present disclosure.
[0011] [Diagram 2] FIG. 1 is a schematic top view of a bag according to certain embodiments of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] In various aspects, the present disclosure relates to a container having an inner surface comprising a fluoropolymer having a plurality of functional groups attached thereto and a first aptamer sequence attached to each of at least some of the functional groups. The container of the present disclosure can be provided in several forms. One particularly convenient form is, for example, a bag formed from one or more sheets of the fluoropolymer material described herein. Those skilled in the art are familiar with bag structures such as those used in cell culture, and will be able to adapt conventional bag structures for use with the bags and methods of the present disclosure based on the description herein. Of course, those skilled in the art will understand that the container of the present disclosure can be provided in several other forms, such as flasks, tubes, dishes.
[0013] One embodiment of such a container in the form of a bag is shown in schematic top view (top) and cross-sectional view (bottom) in FIG. 1. The bag 100 in FIG. 1 includes a bag wall 110 having an exterior surface 112 and an interior surface 114, and further includes ports 130 and 140 located at opposite ends of the bag for adding or removing media to or from the bag. Those skilled in the art will appreciate that the number and location of the ports are not particularly limited and may therefore be located for convenience of use or manufacture, for example. The bag 100 may be the product of two fluoropolymer-containing sheets (e.g., two sheets having a layer of fluorinated ethylene propylene on their inner surfaces) bonded together at their edges (e.g., by laser welding, corona discharge, radiation, heat or melt lamination, etching, plasma treatment, wetting, adhesives, or combinations thereof) to form the compartment 120. The ports 130 and 140 may be sealable to provide the sealed compartment 120.
[0014] The bag wall 110 may be uniform in its composition or, alternatively, may include two or more distinct domains (e.g., two or more layers). For example, two fluoropolymer sheets may be bonded together and then coated to provide an exterior surface 112 that is compositionally distinct from the interior surface 114. Similarly, two multi-layer sheets may be bonded together to provide an exterior surface 112 that is compositionally distinct from the interior surface 114. The multi-layer sheets may be formed from both fluoropolymer and non-fluorinated polymer materials. In such cases, the interior surface of one or more of the multi-layer sheets may be provided with a fluoropolymer layer. The thickness of the bag wall 110, the volume of the compartment 120, and the shape of the bag 100 and / or the compartment 120 are not particularly limited and may be selected for convenience of use or manufacturing and / or to suit a particular application. For example, the thickness of the container wall may be in the range of 0.0003 inches to 0.2 inches in certain embodiments, and the volume of the compartment may be in the range of 100 mL to 100 L in certain embodiments.
[0015] 2 shows several exemplary embodiments of culture bag configurations suitable for use with the bags and methods of the present disclosure. Bag 200a has only a single port 230a, providing access to compartment 220a. Bag 200b is in a so-called "serpentine" configuration that can provide a longer path length through the system, with ports 230b and 240b connected by a serpentine path formed by serpentine-shaped compartment 220b formed by appropriate welding of the sheets forming the bag. Also, bag 200c has a non-rectangular shape and has a corresponding non-rectangular compartment 220c between ports 230c and 240c.
[0016] One or more of the walls of the container may be porous, e.g., permeable to gases (e.g., O2, CO2) produced and consumed in the cell culture, but impermeable to liquids (e.g., water). This may allow for passive exchange of gases with the atmosphere across the container wall to allow respiration of the cells within the bag.
[0017] The container of the present disclosure is desirably formed to be substantially free of contamination of the fluid within the container. Thus, the interior surface of the container is desirably formed from a material that does not leach organic matter into the fluid. For example, in certain embodiments described elsewhere herein, the interior surface of the container wall is formed from a polymer (e.g., a fluoropolymer such as fluorinated ethylene propylene) having a total organic carbon (TOC) in water of less than 0.1 mg / cm2 (e.g., less than 0.05 mg / cm2, or less than 0.05 mg / cm2). Such containers are described, for example, in U.S. Patent Application Publication Nos. 2016 / 0178490 and 2016 / 0178491, each of which is incorporated herein by reference in its entirety. One of ordinary skill in the art can adapt such containers for use with the containers and methods of the present disclosure based on the description herein.
[0018] As used herein, TOC is measured for the container used in the disclosed system, including, for example, extraction from the area of the interior surface of the container (results evaluated as mg / cm2 are TOC per square centimeter of interior area). TOC is measured according to United States Pharmacopeia (USP) 643 using an apparatus that utilizes a high-temperature wet oxidation reaction of UV-assisted chemical oxidation (Ultra-Clean Technology Handbook: Vol. 1: Ultra-Pure Water, Ohmi, Tadahiro; CRC Press, 1993, pp. 497-517). Purified water is contacted with the polymer at 70°C for 24 hours, for example, in a ratio of 1 mL of water to 3 cm2 of the surface area of the article. The water is removed from contact with the polymer and tested with a TOC analyzer. A suitable instrument is the TEKMAR DOHRMANN Model Phoenix 8000 TOC analyzer.
[0019] As described above, the interior surface of the container comprises a plurality of functional groups attached to the fluoropolymer. For example, the fluoropolymer of the interior surface may be functionalized with carboxyl groups, hydroxyl groups, aldehyde groups, carbonyl groups, amine groups, imine groups, amide groups, ester groups, anhydride groups, thiol groups, disulfide groups, phenol groups, guanidine groups, thioether groups, indole groups, imidazole groups, aminoethylamide groups, alkyne groups, alkene groups, aziridine groups, epoxy groups, isonitrile groups, isocyanide groups, tetrazine groups, diazonium surface groups, alkyne groups, alkene groups, aziridine groups, epoxy groups, isonitrile groups, isocyanide groups, tetrazine groups, alkyl groups, aminoethylamide groups, ester groups, or any mixture thereof. For example, in certain such embodiments, the functional groups comprise aldehyde groups. In certain embodiments described elsewhere herein, the functional groups comprise nitrogen-containing groups. For example, in certain such embodiments, the interior surface of the container comprises a plurality of amine groups. One of skill in the art will understand that these "functional groups" are specified as groups to which an aptamer sequence is attached. For example, an "amine" functional group can be attached to a carboxy-bearing aptamer sequence to form a carboxamide bond to the aptamer sequence.
[0020] Those skilled in the art will appreciate that functional groups can be provided to the fluoropolymer surface in many ways. In certain embodiments described elsewhere herein, the functional groups on the interior surface of the container are the product of etching the fluoropolymer. For example, in certain such embodiments, the etching includes chemical etching, physical-mechanical etching, or plasma etching. For example, in certain embodiments, the functional groups that make up the interior surface are the product of chemical etching of the fluoropolymer. In certain such embodiments, the chemical etching includes etching with sodium ammonia or sodium naphthalene. In another example, in certain embodiments, the functional groups that make up the interior surface are the product of physical-mechanical etching. In certain such embodiments, the physical-mechanical etching includes sandblasting or air ablation with silica. In another example, the functional groups that make up the interior surface are the product of plasma etching. In certain such embodiments, the plasma etching includes etching with reactive plasmas such as hydrogen, oxygen, acetylene, methane, and mixtures thereof with nitrogen, argon, and helium.
[0021] In certain embodiments described elsewhere herein, the functional groups on the interior surface of the container are the product of activation of the fluoropolymer in the presence of reactive species. For example, in certain such embodiments, the activation is plasma activation. In certain embodiments, the plasma activation includes the formation of reactive species on the fluoropolymer by treatment with a gas, such as, for example, argon, hydrogen, nitrogen, carbon dioxide, oxygen, and mixtures thereof. In certain embodiments, the plasma activation generates radicals and / or peroxides on the fluoropolymer. The plasma activation can be performed in certain embodiments at a pressure in the range of 0.1 Torr to 0.6 Torr, or in the range of 700 Torr to 760 Torr. As another example, in certain such embodiments, the activation is corona activation. In certain embodiments, the corona activation includes the activation of the fluoropolymer under a gas, such as, for example, argon, nitrogen, hydrogen, and mixtures thereof, to form active sites (e.g., reactive species or susceptible to subsequent chemical treatment) on the fluoropolymer. In certain embodiments, activation (e.g., plasma activation or corona activation) includes reactive hydrocarbon vapors such as, for example, ketones, alcohols, p-chlorostyrene, acrylonitrile, propylenediamine, anhydrous ammonia, styrene sulfonic acid, carbon tetrachloride, tetraethylenepentamine, cyclohexylamine, tetraisopropyl titanate, decylamine, tetrahydrofuran, diethyltriamine, tertiary butylamine, ethylenediamine, toluene-2,4-diisocyanate, glycidyl methacrylate, triethylenetetramine, hexane, triethylamine, methyl alcohol, vinyl acetate, methylisopropylamine, vinyl butyl ether, methyl methacrylate, 2-vinylpyrrolidone, methyl vinyl ketone, xylene, or mixtures thereof. In certain embodiments described elsewhere herein, activation (e.g., plasma activation) with polymerizable hydrocarbon vapors selected from, for example, butylene, ethylene, glutaraldehyde, and the like, results in a polymer (i.e., containing functional groups as described elsewhere herein) coated onto the fluoropolymer.Those skilled in the art will appreciate that in certain embodiments, plasma activation (i.e., plasma polymerization) involving polymerizable hydrocarbon vapors can result in relatively disordered, highly crosslinked polymer coatings.
[0022] In certain embodiments described elsewhere herein, the functional groups on the interior surface of the container are the product of chemical treatment of an activated fluoropolymer. For example, in certain such embodiments, the activated fluoropolymer is the product of plasma activation or corona activation of the fluoropolymer. In certain such embodiments, the chemical treatment is a chemical reaction, such as, for example, graft polymerization, coupling, click chemistry, condensation, or addition. In certain such embodiments, the chemical treatment is graft polymerization in solution, including polymerizing a vinyl monomer via radical polymerization (e.g., initiated by radicals generated by plasma activation of the fluoropolymer). In certain such embodiments, the vinyl monomer is selected from, for example, acrylic acid, (meth)acrylates, (meth)alkyl acrylates, styrenes, dienes, alpha-olefins, halogenated alkenes, (meth)acrylonitrile, acrylamides, N-vinylcarbazole, N-vinylpyrrolidone, and maleic anhydride. For example, radical polymerization of acrylic acid monomers on the fluoropolymer can, in certain embodiments, achieve a high density surface of carboxyl groups. In certain embodiments, such polymerization products can be relatively ordered (eg, as compared to plasma polymerization products).
[0023] In certain embodiments described elsewhere herein, the functional groups on the interior surface of the container are the product of a coating of an activated fluoropolymer. For example, in certain such embodiments, the activated fluoropolymer is the product of plasma activation or corona activation of a fluoropolymer. In certain such embodiments, the coating is a wet coating, a powder coating, or chemical vapor deposition. In certain embodiments, the coating is plasma enhanced chemical vapor deposition or chemical vapor deposition using an initiator.
[0024] As described above, the interior surface of the container comprises a first aptamer sequence having a binding affinity for the viral vector, the sequence being attached to at least some of the functional groups (i.e., attached to the fluoropolymer as described elsewhere herein). As used herein, an "aptamer sequence" comprises a nucleotide sequence that can selectively bind to one or more target sites (e.g., on a viral capsid, a cell surface, etc.) via non-covalent interactions (e.g., electrostatic interactions, hydrophobic interactions, shape complementarity). In certain embodiments, the aptamer sequence comprises an individual oligonucleotide. In other embodiments, two or more repeats of the aptamer sequence comprise a polynucleotide.
[0025] As used herein, "viral vector" includes viruses (e.g., lentivirus, retrovirus) that contain a nucleotide sequence and can introduce the nucleotide sequence into a target cell. One of skill in the art will understand that the surface of such viruses can include one or more molecules to which an aptamer sequence can bind. In certain embodiments described elsewhere herein, the first aptamer sequence has a binding affinity of at least 0.1 nM to the viral vector. For example, in certain such embodiments, the first aptamer sequence has a binding affinity of at least 0.25 nM, or at least 0.5 nM, 0.75 nM, or at least 1 nM, or at least 2.5 nM, or at least 5 nM, or at least 10 nM, or at least 25 nM, or at least 50 nM, or at least 75 nM, or at least 100 nM to the viral vector. One of skill in the art can select a binding affinity that results in a desired degree of binding of the viral vector to the inner surface of the container.
[0026] In certain embodiments described elsewhere herein, the interior surface of the container further comprises a second aptamer sequence having a binding affinity to a cell receptor selected from VLA-4 and VLA-5, the sequence being attached to a portion of the functional group (i.e., attached to a fluoropolymer, as described elsewhere herein). In certain embodiments described elsewhere herein, the second aptamer sequence has a binding affinity to the cell receptor of at least 0.1 nM. For example, in certain such embodiments, the first aptamer sequence has a binding affinity to the cell receptor of at least 0.25 nM, or at least 0.5 nM, 0.75 nM, or at least 1 nM, or at least 2.5 nM, or at least 5 nM, or at least 10 nM, or at least 25 nM, or at least 50 nM, or at least 75 nM, or at least 100 nM.
[0027] One skilled in the art will appreciate that such aptamers (i.e., to both the viral vector and the target) can be prepared according to commonly known procedures, such as, for example, the SELEX methodology. One skilled in the art can select a binding affinity that results in a desired degree of binding of a desired type of cell to the interior surface of the container.
[0028] By binding both the first and second aptamer sequences to the interior surface of the container, the viral vector and the cells desired to be transduced with the viral vector can be co-located near each other, thereby simplifying transduction. As described in more detail below, the aptamer sequences can be separately bound to the surface on separate aptamer molecules, or in other embodiments, can be brought together on the same aptamer molecule.
[0029] In certain embodiments described elsewhere herein, the first aptamer sequence is at least 5 base pairs long.For example, in certain such embodiments, the first aptamer sequence is at least 10, or at least 15, or at least 20, or at least 25, or at least 30 base pairs long.In certain embodiments described elsewhere herein, the second aptamer sequence is at least 5 base pairs long.For example, in certain such embodiments, the second aptamer sequence is at least 10, or at least 15, or at least 20, or at least 25, or at least 30 base pairs long.
[0030] In certain embodiments described elsewhere herein, at least some of the functional groups are directly attached (i.e., via covalent bonds) to the oligonucleotides that contain the first and / or second aptamer sequences. For example, in certain such embodiments, the inner surface comprises a plurality of oligonucleotides, each of which contains the first and / or second aptamer sequences, and each of which is attached to the functional groups of the fluoropolymer via covalent bonds (e.g., to amine groups). In certain such embodiments, each oligonucleotide comprises the first aptamer sequence but not the second aptamer sequence, comprises the second aptamer sequence but not the first aptamer sequence; or comprises both the first and second aptamer sequences. For example, in certain such embodiments, the interior surface comprises a first plurality of oligonucleotides, each comprising a first aptamer sequence, each attached via a covalent bond to a functional group of the fluoropolymer (e.g., to an amine group), and a second plurality of oligonucleotides, each further comprising a second aptamer sequence, each attached via a covalent bond to a functional group of the fluoropolymer (e.g., to an amine group). When different oligonucleotides are used for the first and second aptamer sequences, they can be attached to the fluoropolymer using the same chemistry or using different chemistry. In other such embodiments, the interior surface comprises a plurality of oligonucleotides, each comprising a first aptamer sequence and / or a second aptamer sequence, each attached via a covalent bond to a functional group of the fluoropolymer (e.g., to an amine group).
[0031] In other embodiments, non-covalent bonds can be used to attach the aptamer sequences to the inner surface of the container, for example using non-covalent associations such as (strept)avidin / biotin.
[0032] In certain embodiments described elsewhere herein, the average concentration of oligonucleotides (e.g., including the first aptamer sequence and / or the second aptamer sequence) on the interior surface of the container is at least 50 oligonucleotides per square micron of surface. For example, in certain embodiments, the average concentration of oligonucleotides is at least 60, at least 70, at least 80, at least 90, at least 100, at least 250, at least 500, at least 750, or at least 1,000 oligonucleotides per square micron of interior surface of the container. One skilled in the art will select the oligonucleotide concentration(s) that results in the desired degree of viral vector and cell binding to allow for the desired degree of transduction.
[0033] In certain embodiments described elsewhere herein, at least some of the functional groups are directly linked to a polynucleotide that comprises two or more repeats of the first aptamer sequence.For example, in certain such embodiments, the inner surface comprises a plurality of polynucleotides, each of which comprises two or more repeats of the first aptamer sequence, and each of which is linked to a functional group of the fluoropolymer (e.g., to an amine group) via a covalent bond.In certain such embodiments, each polynucleotide comprises at least 10, or at least 25, or at least 50, or at least 75, or at least 100, or at least 200, or at least 300, or at least 400, or at least 500, or at least 750, or at least 1000 repeats of the first aptamer sequence.
[0034] Similarly, in certain embodiments described elsewhere herein, each of the functional groups is directly linked to a polynucleotide that includes two or more repeats of a second aptamer sequence. For example, in certain such embodiments, the interior surface includes a first plurality of polynucleotides (each of which includes two or more repeats of a first aptamer sequence, each of which is linked to a functional group of a fluoropolymer via a covalent bond (e.g., to an amine group), and further includes a second plurality of polynucleotides (each of which includes two or more repeats of a second aptamer sequence, each of which is linked to a functional group of a fluoropolymer via a covalent bond (e.g., to an amine group). In certain such embodiments, each polynucleotide comprises at least 10, or at least 25, or at least 50, or at least 75, or at least 100, or at least 200, or at least 300, or at least 400, or at least 500, or at least 750, or at least 1000 repeats of the first aptamer sequence or the second aptamer sequence.
[0035] Polynucleotides containing multiple repeats of a given aptamer sequence can be generated by rolling circle amplification (RCA) of templates corresponding to the desired aptamer sequence, starting with a nucleotide primer covalently attached (e.g., via an amine group) to a fluoropolymer.
[0036] In certain embodiments described elsewhere herein, at least some of the functional groups are directly attached to a polynucleotide that comprises at least one repeat of each of the first and second aptamer sequences.For example, in certain such embodiments, the polynucleotide is the product of rolling circle amplification (RCA) of a template that corresponds to the first and second aptamer sequences in succession, starting from a nucleotide primer that is covalently attached (e.g., via an amine group) to a fluoropolymer.In certain such embodiments, each polynucleotide comprises at least 10, or at least 25, or at least 50, or at least 75, or at least 100, or at least 200, or at least 300, or at least 400, or at least 500, or at least 750, or at least 1000 total repeats of the first and second aptamer sequences. In certain embodiments, the polynucleotide comprises an alternating series of repeats of a first aptamer sequence and a second aptamer sequence. Of course, in other embodiments, the polynucleotide comprises one or more blocks of two or more consecutive repeats of the first aptamer sequence and one or more blocks of two or more consecutive repeats of the second aptamer sequence.
[0037] In certain such embodiments, the average concentration of polynucleotides (e.g., including repeats of the first aptamer sequence and / or the second aptamer sequence) occupying the interior surface of the container is at least 50 polynucleotides per square micron of surface. For example, in certain embodiments, the average concentration of polynucleotides is at least 60, at least 70, at least 80, at least 90, at least 100, at least 250, at least 500, at least 750, or at least 1,000 polynucleotides per square micron of the interior surface of the container.
[0038] In certain embodiments described elsewhere herein, at least a portion of the functional groups are each linked to at least one oligonucleotide comprising a first aptamer sequence via a linker. In certain such embodiments, the linker comprises a polypeptide or a polynucleotide. For example, in certain embodiments, the interior surface comprises a plurality of linkers (e.g., polypeptides or polynucleotides) covalently bonded to functional groups (e.g., amine groups) of the fluoropolymer, each linker being linked to at least one oligonucleotide comprising a first aptamer sequence. In certain embodiments described elsewhere herein, at least a portion of the functional groups are each linked to at least one oligonucleotide comprising a second aptamer sequence via a linker. For example, in certain such embodiments, the interior surface comprises a first plurality of linkers (e.g., polypeptides or polynucleotides) attached to the fluoropolymer (e.g., to amine groups) via covalent bonds (each linker is attached to at least one oligonucleotide comprising a first aptamer sequence), and further comprises a second plurality of linkers (e.g., polypeptides or polynucleotides) attached to functional groups of the fluoropolymer (e.g., to amine groups) via covalent bonds (each linker is attached to at least one oligonucleotide comprising a second aptamer sequence). In another example, in certain such embodiments, the interior surface comprises a plurality of linkers (e.g., polypeptides or polynucleotides) attached to functional groups of the fluoropolymer (e.g., to amine groups) via covalent bonds, each linker is attached to at least one oligonucleotide comprising at least one oligonucleotide comprising a first aptamer sequence and a second aptamer sequence. Linkers can also be used in non-covalent interactions, for example, by (strept)avidin / biotin interactions.
[0039] In certain such embodiments, at least two oligonucleotides (e.g., comprising a first aptamer sequence and / or a second aptamer sequence) are attached to each of at least a portion of the linker. For example, in certain embodiments, at least 5, at least 10, at least 20, at least 30, at least 40, or at least 50 oligonucleotides are attached to each of at least a portion of the linker.
[0040] In certain such embodiments, the average concentration of linkers (e.g., having a first aptamer sequence and / or a second aptamer sequence bound thereto) occupying the interior surface of the container is at least 50 linkers per square micron of surface. For example, in certain embodiments, the average concentration of linkers is at least 60, at least 70, at least 80, at least 90, at least 100, at least 250, at least 500, at least 750, or at least 1,000 linkers per square micron of the interior surface of the container.
[0041] Various fluoropolymers can be used in the interior surface of the container described herein. In certain embodiments described elsewhere herein, the interior surface of the container comprises a fluoropolymer selected from polytetrafluoroethylene (PTFE), perfluoroalkoxy (PFA), ethylene tetrafluoroethylene (ETFE), polyvinylidene fluoride (PVDF), polychlorotrifluoroethylene (PCTFE), ethylene chlorotrifluoroethylene (ECTFE), fluorinated ethylene propylene (FEP), ethylene fluorinated ethylene propylene (EFEP), perfluoropolyether (PFPE), modified polytetrafluoroethylene (TFM), polyvinyl fluoride (PVF), or any mixture thereof. For example, in certain embodiments described elsewhere herein, the interior surface of the container comprises fluorinated ethylene propylene. In certain embodiments described elsewhere herein, the interior surface of the container consists essentially of a fluoropolymer (e.g., fluorinated ethylene propylene) and a functional group and an aptamer sequence attached thereto. In certain embodiments described elsewhere herein, the fluoropolymer material of the interior surface of the container has a thickness of at least 0.0003 inches, at least 0.0004 inches, at least 0.0005 inches, at least 0.0006 inches, at least 0.001 inches, or at least 0.10 inches. For example, in certain such embodiments, the material occupying the interior surface of the container has a thickness in the range of 0.0003 inches to 0.2 inches, or 0.0003 inches to 0.1 inches, or 0.0005 inches to 0.08 inches, or 0.001 inches to 0.07 inches, or 0.001 inches to 0.05 inches, or 0.001 inches to 0.03 inches, or 0.001 inches to 0.018 inches, or 0.001 inches to 0.016 inches, or 0.001 inches to 0.014 inches, or 0.001 inches to 0.012 inches.
[0042] In certain embodiments described elsewhere herein, the material making up the container wall is a multi-layer material having a layer of fluoropolymer on its inner surface and a layer of another polymeric material (fluoropolymer or other) on its outer surface. In certain embodiments described elsewhere herein, the material of the outer surface of the container has a thickness of at least 0.0005 inches, or at least 0.001 inches, or at least 0.005 inches, or at least 0.0075 inches, or at least 0.01 inches, or at least 0.02 inches, or at least 0.03 inches, or at least 0.04 inches, or at least 0.05 inches, or at least 0.06 inches, or at least 0.07 inches, or at least 0.08 inches, or at least 0.09 inches, or at least 0.1 inches, or at least 0.11 inches. For example, in certain such embodiments, the material of the exterior surface of the container has a thickness in the range of 0.0005 inches to 0.2 inches, or 0.005 inches to 0.18 inches, or 0.01 inches to 0.16 inches, or 0.01 inches to 0.14 inches, or 0.01 inches to 0.12 inches, or 0.06 inches to 0.13 inches, or 0.09 inches to 0.126 inches.
[0043] In certain embodiments described elsewhere herein, the exterior surface of the container comprises a material other than a fluoropolymer. For example, in certain such embodiments, the material of the exterior surface of the container comprises a thermoplastic polymer, a thermoplastic elastomer, a silicone, a rubber, or any combination thereof. Alternatively, the exterior surface of the container may comprise a fluoropolymer, such as the fluoropolymer of the interior surface or a different fluoropolymer, in certain embodiments described elsewhere herein. In certain such embodiments, the material of the interior and exterior surfaces (e.g., the container wall) consists essentially of a fluoropolymer (e.g., fluorinated ethylene propylene), and functional groups and aptamer sequences attached to the interior surface.
[0044] In certain embodiments described elsewhere herein, the container further comprises an aqueous medium. The aqueous medium can be, for example, a cell culture medium comprising a viral vector (e.g., as described elsewhere herein) and optionally a target cell. As used herein, a "target cell" includes a cell susceptible to transduction by a viral vector. In certain embodiments, the target cell comprises one or more of VLA-4 and VLA-5 surface receptors. Thus, in certain embodiments described elsewhere herein, the container comprises a viral vector (e.g., comprising a lentivirus or a retrovirus). In certain embodiments described elsewhere herein, the container comprises a target cell (e.g., comprising one or more of VLA-4 and VLA-5 surface receptors).
[0045] Advantageously, the inventors have found that the containers described herein can facilitate co-localization of the viral vector and the target cells involved in the transduction method, desirably enhancing its efficiency without requiring the user to perform a manual coating process immediately prior to transduction. Thus, another aspect of the present disclosure is a transduction method comprising including a viral vector and a target cell in a container as described elsewhere herein. In certain such embodiments, the container comprises an aqueous medium (e.g., cell culture medium). In certain such embodiments, the viral vector comprises a lentivirus or a retrovirus. In certain such embodiments, the target cell comprises one or more of VLA-4 and VLA-5 surface receptors.
[0046] In certain embodiments described elsewhere herein, the transduction method includes including a suspension of a viral vector (e.g., a viral vector supernatant) in a first aqueous medium in a container; and then incubating the container containing the viral vector for a first period of time. The first period of time can be any length sufficient to allow association of at least a portion of the viral vector with a first aptamer sequence on the interior surface of the container. For example, in certain embodiments, the container containing the viral vector is incubated, e.g., at a temperature in the range of 32-37°C, for at least 1 hour, or at least 2 hours, or at least 3 hours, or at least 4 hours, or at least 5 hours. After incubating for the first period of time, the method includes adding target cells to the container (e.g., as a suspension in a second aqueous medium); and then incubating the container containing the target cells and viral vector for a second period of time. The second period of time can be any length sufficient to allow transduction of at least a portion of the target cells. For example, in certain embodiments, the vessel containing the viral vector and target cells is incubated for at least 6 hours, or at least 12 hours, or at least 18 hours, or at least 1 day, or at least 1.5 days, or at least 2 days, or at least 2.5 days, e.g., at a temperature in the range of 35-39° C. After incubating for the second period of time, the method includes recovering the transduced cells from the vessel.
[0047] In certain such embodiments, the method further includes removing at least a portion of the first aqueous medium after incubating the container for a first period of time; then adding a wash medium to the container; and then removing at least a portion of the wash medium from the container (i.e., before adding the target cells to the container).
[0048] In other embodiments, the transduction method includes including in a container a suspension of viral vector and target cells in a first aqueous medium (e.g., a mixture of viral vector supernatant and target cells); and then incubating the container containing the target cells and viral vector for a first period of time. The first period of time can be any length sufficient to allow transduction of at least a portion of the target cells. For example, in certain embodiments, the container containing the viral vector and target cells is incubated for at least 6 hours, or at least 12 hours, or at least 18 hours, or at least 1 day, or at least 1.5 days, or at least 2 days, or at least 2.5 days, e.g., at a temperature in the range of 35-39°C. After incubating for the first period of time, the method includes recovering the transduced cells from the container.
[0049] In certain embodiments described elsewhere herein, harvesting the transduced cells includes removing a suspension of the transduced cells from the vessel. In certain embodiments, harvesting the transduced cells includes adding a cell dissociation medium to the vessel (e.g., after removing at least a portion of the transduction medium from the vessel) and then removing a suspension of the transduced cells in the cell dissociation medium from the vessel. Dissociating the cells can include one or more dissociation agents capable of releasing the target cells from the interior surface of the vessel. For example, in certain such embodiments, the cell dissociation medium includes one or more of a salt and a chelating agent (e.g., capable of disrupting binding of the second aptamer sequence to the target cells). In another example, in certain such embodiments, the cell dissociation medium includes one or more restriction enzymes (e.g., capable of degrading an oligo- or polynucleotide comprising the second aptamer sequence). In another example, in certain such embodiments, the cell dissociation medium comprises an oligo- or polynucleotide comprising a nucleotide sequence complementary to a second aptamer sequence (e.g., capable of displacing bound target cells from the second aptamer sequence).
[0050] Various aspects and embodiments of the present disclosure are provided by the following enumerated list of embodiments, which may be combined in any number and in any combination that is not logically and scientifically consistent. Embodiment 1. A container (e.g., a bag) having an exterior surface and an interior surface, the interior surface being: Fluoropolymers; A plurality of functional groups attached to the fluoropolymer; and a first aptamer sequence bound to each of at least a portion of the functional groups and having binding affinity for the viral vector; 3. A container comprising: Embodiment 2. The container of embodiment 1, wherein the interior surface further comprises a second aptamer sequence having binding affinity for a cellular receptor selected from VLA-4 and VLA-5, attached to a portion of the functional group. Embodiment 3. The container of embodiment 1 or 2, wherein at least a portion of the functional groups are each directly attached to an oligonucleotide comprising the first aptamer sequence and / or the second aptamer sequence. Embodiment 4. The container of embodiment 1 or 2, wherein at least a portion of the functional groups are each directly attached to a polynucleotide comprising two or more repeats of the first aptamer sequence or the second aptamer sequence. Embodiment 5. The container of embodiment 4, wherein the polynucleotide comprises at least one repeat of each of the first and second aptamer sequences. Embodiment 6. The container of embodiment 4 or 5, wherein the polynucleotide comprises at least 10, at least 100, or at least 500 repeats of the first aptamer sequence or the second aptamer sequence. Embodiment 7. The container of embodiment 1 or 2, wherein each of at least a portion of the functional groups is attached via a linker to at least one oligonucleotide comprising the first aptamer sequence and / or the second aptamer sequence. Embodiment 8. The container of embodiment 7, wherein each of at least a portion of the functional groups is attached via a linker to at least one oligonucleotide comprising a first aptamer sequence and at least one oligonucleotide comprising a second aptamer sequence. Embodiment 9. The container of embodiment 7 or 8, wherein at least 2, at least 5, at least 10, or at least 50 oligonucleotides are attached to each of at least a portion of the linker. Embodiment 10. The container of embodiment 7 or 8, wherein the linker comprises a polypeptide or a polynucleotide. Embodiment 11. A container according to any of the preceding embodiments, wherein the functional group is a product of etching of a fluoropolymer. Embodiment 12. The container of embodiment 11, wherein the etching is chemical etching, physical mechanical etching, or plasma etching. Embodiment 13. A container according to any of the preceding embodiments, wherein the functional group is the product of activation of the fluoropolymer in the presence of a reactive species. Embodiment 14. The activation is plasma activation or corona activation; the reactive species comprises one or more reactive hydrocarbon vapors; 14. A container as described in embodiment 13. Embodiment 15. The activation is plasma activation; the reactive species comprises one or more polymerizable hydrocarbon vapors (e.g., selected from butylene, ethylene, and glutaraldehyde); 14. A container as described in embodiment 13. Embodiment 16. The container of any of embodiments 1 to 10, wherein the functional group is the product of chemically treating an activated fluoropolymer. Embodiment 17. The activated fluoropolymer is the product of plasma activation or corona activation; The chemical treatment is graft polymerization, coupling, click chemistry, condensation, or addition; 17. A container as described in embodiment 16. Embodiment 18. A container according to any of the preceding embodiments, wherein the functional group is the product of coating with an activated fluoropolymer. Embodiment 19. The activated fluoropolymer is the product of plasma activation or corona activation; The coating is a wet coating, a powder coating, or a chemical vapor deposition; 19. A container as described in embodiment 18. Embodiment 20. The container of any of embodiments 1 to 19, wherein the functional groups comprise one or more of a carboxyl group, a hydroxyl group, an aldehyde group, a carbonyl group, an amine group, an imine group, an amide group, an ester group, an anhydride group, a thiol group, a disulfide group, a phenol group, a guanidine group, a thioether group, an indole group, an imidazole group, an aminoethylamide group, an alkyne group, an alkene group, an aziridine group, an epoxy group, an isonitrile group, an isocyanide group, a tetrazine group, a diazonium surface group, an alkyne group, an alkene group, an aziridine group, an epoxy group, an isonitrile group, an isocyanide group, a tetrazine group, an alkyl group, an aminoethylamide group, or an ester group. Embodiment 21. A container according to any one of embodiments 1 to 19, wherein the functional groups include one or more of a carboxyl group, a hydroxyl group, an aldehyde group, an amine group, an imine group, an amide group, and an ester group. Embodiment 22: The container of any of embodiments 1 to 19, wherein the functional group comprises an amine group. Embodiment 23. A container according to any of the preceding embodiments, wherein the attachment of the functional group (e.g., to the oligomer, polynucleotide, or linker) is a covalent bond. Embodiment 24. The container of any of embodiments 1 to 23, wherein the fluoropolymer is polytetrafluoroethylene (PTFE), perfluoroalkoxy (PFA), ethylene tetrafluoroethylene (ETFE), polyvinylidene fluoride (PVDF), polychlorotrifluoroethylene (PCTFE), ethylene chlorotrifluoroethylene (ECTFE), fluorinated ethylene propylene (FEP), ethylene fluorinated ethylene propylene (EFEP), perfluoropolyether (PFPE), modified polytetrafluoroethylene (TFM), polyvinyl fluoride (PVF), or any mixture thereof. Embodiment 25. The container of any one of embodiments 1 to 23, wherein the fluoropolymer is fluorinated ethylene propylene. Embodiment 26. The container of any of the preceding embodiments, wherein the fluoropolymer has a TOC in water of 0.1 mg / cm2. Embodiment 27. A container according to any one of embodiments 1 to 26, wherein the viral vector comprises a lentivirus or a retrovirus. Embodiment 28. A container according to any one of embodiments 1 to 27, comprising an aqueous medium. Embodiment 29. A container according to embodiment 28, comprising a viral vector (e.g., including a lentivirus or a retrovirus). Embodiment 30. A container according to embodiment 28 or 29, comprising target cells (e.g., comprising one or more of VLA-4 and VLA-5 surface receptors). Embodiment 31. A method of transduction comprising containing a viral vector and target cells in a container according to any one of embodiments 1 to 29. Embodiment 32. The method of transduction described in embodiment 31, wherein the viral vector comprises a lentivirus or a retrovirus. Embodiment 33. A method of transduction according to embodiment 31 or 32, wherein the target cells contain one or more VLA-4 or VLA-5 surface receptors. Embodiment 34. A method of transduction according to any one of embodiments 31 to 33, comprising: containing in a container a suspension of a viral vector in a first aqueous medium; incubating the container containing the viral vector for a first period of time; adding the target cells to the vessel (e.g., as a suspension in a second aqueous medium); incubating the vessel containing the target cells and the viral vector for a second period of time; and then Harvesting the transduced cells from the vessel A method comprising: Embodiment 35. After incubating the container for a first period of time, removing at least a portion of the first aqueous medium; and then adding the cleaning medium to the container; then removing at least a portion of the cleaning medium from the container; and then Adding target cells to the vessel The transduction method of embodiment 34, further comprising: Embodiment 36. Containing in a container a suspension of viral vectors and target cells in a first aqueous medium; incubating the vessel containing the target cells and the viral vector for a first period of time; and then Harvesting the transduced cells from the vessel 34. The method of transduction according to any one of embodiments 31 to 33, comprising: Embodiment 37. Recovering the transduced cells from the container comprises: adding a cell dissociation medium to the vessel; and then Removing the transduced cell suspension from the vessel 37. The method of transduction according to any one of embodiments 31 to 36, comprising: Embodiment 38. The method of transduction described in embodiment 37, wherein the cell dissociation medium comprises one or more of a salt and a chelating agent. Embodiment 39. The method of transduction described in embodiment 37, wherein the cell dissociation medium comprises one or more restriction enzymes. Embodiment 40. The transduction method of embodiment 37, wherein the cell dissociation medium comprises an oligo- or polynucleotide comprising a nucleotide sequence complementary to the second aptamer sequence. Embodiment 41: The container or the method of any one of embodiments 1 to 39, wherein the container is in the form of a bag.
[0051] The details shown in this specification are by way of example and merely for illustrative discussion of preferred embodiments of the present invention, and are presented to provide what is believed to be the most useful and easily understood explanation of the principles and conceptual aspects of various embodiments of the present invention. In this regard, no attempt has been made to show the structural details of the present invention in more detail than necessary for a fundamental understanding of the present invention, and the description using drawings and / or examples will make it clear to those skilled in the art how some forms of the present invention may be embodied in practice. Thus, before the disclosed methods and devices are described, it should be understood that the aspects described herein are not limited to specific embodiments, devices, or configurations, which may, of course, vary. It should also be understood that the terminology used in this specification is for the purpose of describing specific aspects only, and is not intended to be limiting unless specifically defined in this specification.
[0052] The terms "a", "an", "the" and similar referents used in the context of describing the present invention (particularly in the context of the claims that follow) should be construed to encompass both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The recitation of ranges of values herein is merely intended to serve as a shorthand method of individually referring to each separate value falling within the range. Unless otherwise indicated herein, each separate value is incorporated herein as if it were individually recited herein. It will be further understood that the endpoints of each range are meaningful both in relation to the other endpoint, and independently of the other endpoint.
[0053] All methods described herein can be carried out in any suitable order of steps unless otherwise indicated herein or clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended merely to better clarify the invention and does not limit the scope of the invention as otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
[0054] Unless the context clearly requires otherwise, throughout the specification and claims, words such as "comprise," "comprising," and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is, meaning "including, but not limited to." Words using the singular or plural also include the plural and singular, respectively. Furthermore, the words "herein," "above," and "below," and words of similar import, when used in this application, shall refer to this application as a whole and not to any particular portions of this application.
[0055] As will be understood by one of ordinary skill in the art, each embodiment disclosed herein can comprise, consist essentially of, or consist of its particular described elements, steps, ingredients, or components. As used herein, the transitional terms "comprise" or "comprises" mean including but not limited to, and can include even large amounts of unspecified elements, steps, ingredients, or components. The transitional phrase "consisting of" excludes any unspecified elements, steps, ingredients, and components. The transitional phrase "consisting essentially of" limits the scope of the embodiment to the specified elements, steps, ingredients, or components, and those that do not materially affect the embodiment.
[0056] Unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention, and at the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
[0057] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible, however, any numerical values inherently contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0058] Grouping of alternative elements or embodiments of the invention disclosed herein should not be construed as limiting. Each group member may be referenced and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in or deleted from a group for reasons of convenience and / or patentability. When such inclusion or deletion occurs, the specification is deemed to include the modified group and thus fulfill all Markush group descriptions used in the appended claims.
[0059] Several embodiments of the present invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations of these described embodiments will become apparent to those skilled in the art upon reading the foregoing description. The inventors expect such variations to be employed by those skilled in the art as appropriate, and the inventors intend for the invention to be carried out in ways other than as specifically described herein. Accordingly, the present invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, the present invention encompasses any combination of the above-described elements in all possible variations thereof unless otherwise indicated herein or clearly contradicted by context.
[0060] Throughout this specification, several patents and printed publications are referenced. Each of the cited references and printed publications is individually incorporated herein by reference in its entirety.
[0061] Moreover, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, and not of limitation, alternative configurations of the invention may be utilized in accordance with the teachings herein. Thus, the invention is not limited to that precisely as shown and described.
Claims
1. A container (e.g., a bag) having an exterior surface and an interior surface, the interior surface comprising: Fluoropolymer; a plurality of functional groups attached to the fluoropolymer; and a first aptamer sequence bound to each of at least a portion of said functional groups and having binding affinity for the viral vector; 3. A container comprising:
2. 10. The container of claim 1, wherein the interior surface further comprises a second aptamer sequence attached to a portion of the functional group, the second aptamer sequence having binding affinity for a cellular receptor selected from VLA-4 and VLA-5.
3. 10. The container of claim 1, wherein at least a portion of the functional groups are each directly attached to an oligonucleotide comprising the first aptamer sequence and / or the second aptamer sequence.
4. 10. The container of claim 1, wherein at least a portion of the functional groups are each directly attached to a polynucleotide comprising two or more repeats of the first aptamer sequence or the second aptamer sequence.
5. 5. The container of claim 4, wherein the polynucleotide comprises at least one repeat of each of the first and second aptamer sequences.
6. 5. The container of claim 4, wherein the polynucleotide comprises at least 10, at least 100, or at least 500 repeats of the first aptamer sequence or the second aptamer sequence.
7. The container of claim 1, wherein each of at least a portion of the functional groups is linked via a linker to at least one oligonucleotide comprising a first aptamer sequence and at least one oligonucleotide comprising a second aptamer sequence, and at least 10 of the oligonucleotides are linked to each of at least a portion of the linker.
8. The functional group is Products of etching of fluoropolymers; The product of activation of a fluoropolymer in the presence of a reactive species; or Products of chemical treatment of activated fluoropolymers 2. The container of claim 1 .
9. 10. The container of claim 1, wherein the functional groups include one or more of a carboxy group, a hydroxyl group, an aldehyde group, an amine group, an imine group, an amide group, and an ester group.
10. The container of claim 1 , wherein the functional group comprises an amine group.
11. 2. The container of claim 1, wherein the fluoropolymer is polytetrafluoroethylene (PTFE), perfluoroalkoxy (PFA), ethylene tetrafluoroethylene (ETFE), polyvinylidene fluoride (PVDF), polychlorotrifluoroethylene (PCTFE), ethylene chlorotrifluoroethylene (ECTFE), fluorinated ethylene propylene (FEP), ethylene fluorinated ethylene propylene (EFEP), perfluoropolyether (PFPE), modified polytetrafluoroethylene (TFM), polyvinyl fluoride (PVF), or any mixture thereof.
12. 10. The container of claim 1, wherein the fluoropolymer is fluorinated ethylene propylene.
13. The container of claim 1 , comprising an aqueous medium, a viral vector and a target cell.
14. 14. The container of claim 13, wherein the viral vector comprises a lentivirus or a retrovirus and the target cells comprise one or more VLA-4 or VLA-5 surface receptors.
15. A method of transduction comprising placing a viral vector and a target cell in the container of claim 1.
16. The method of transduction of claim 15, wherein the viral vector comprises a lentivirus or a retrovirus and the target cell comprises one or more VLA-4 or VLA-5 surface receptors.
17. providing a container with a suspension of a viral vector in a first aqueous medium; incubating the container containing the viral vector for a first period of time; adding target cells to the vessel (e.g., as a suspension in a second aqueous medium); incubating the vessel containing the target cells and the viral vector for a second period of time; and then Recovering the transduced cells from said vessel. The method of transduction according to claim 15, comprising:
18. After incubating the container for a first period of time, removing at least a portion of the first aqueous medium; and then adding a cleaning medium to said vessel; then removing at least a portion of the cleaning medium from the container; and then adding target cells to said vessel; The method of transduction according to claim 17, further comprising:
19. Recovering the transduced cells from the vessel. adding a cell dissociation medium to the vessel; and then Removing the transduced cell suspension from the vessel. The method of transduction according to claim 17, comprising:
20. containing in a container a suspension of viral vectors and target cells in a first aqueous medium; incubating the vessel containing the target cells and the viral vector for a first period of time; and then Recovering the transduced cells from said vessel. The method of transduction according to claim 15, comprising:
Citation Information
Patent Citations
Methods for enhancing virus-mediated dna transfer using molecules with virus and cell binding sites
JP2000507084A
Capture system of cells and methods
US20160178490A1
Capture system of cells and methods
US20160178491A1
Method for gene introduction into target cells by retrovirus
WO1997018318A1
Gene transfer method with the use of serum-free medium
WO1999005301A1
